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Screening guidelines are used to help identify prediabetes and diabetes before implement-
ing evidence-based prevention and treatment interventions. We examined screening prac-
tices benchmarking against two US guidelines, and the capacity of each guideline to
identify dysglycemia.
Methods
Using 2007–2012 National Health and Nutrition Examination Surveys, we analyzed nation-
ally-representative, cross-sectional data from 5,813 fasting non-pregnant adults aged20
years without self-reported diabetes. We examined proportions of adults eligible for diag-
nostic glucose testing and those who self-reported receiving testing in the past three years,
as recommended by the American Diabetes Association (ADA) and the US Preventive Ser-
vices Task Force (USPSTF-2008) guidelines. For each screening guideline, we also as-
sessed sensitivity, specificity, and positive (PPV) and negative predictive values in
identifying dysglycemia (defined as fasting plasma glucose100 mg/dl or hemoglobin A1c
5.7%).
Results
In 2007–2012, 73.0% and 23.7% of US adults without diagnosed diabetes met ADA and
USPSTF-2008 criteria for screening, respectively; and 91.5% had at least one major risk
factor for diabetes. Of those ADA- or USPSTF-eligible adults, about 51% reported being
tested within the past three years. Eligible individuals not tested were more likely to be
lower educated, poorer, uninsured, or have no usual place of care compared to tested
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eligible adults. Among adults with1 major risk factor, 45.7% reported being tested, and
dysglycemia yields (i.e., PPV) ranged from 45.8% (high-risk ethnicity) to 72.6% (self-re-
ported prediabetes). ADA criteria and having any risk factor were more sensitive than the
USPSTF-2008 guideline (88.8–97.7% vs. 31.0%) but less specific (13.5–39.7% vs. 82.1%)
in recommending glucose testing, resulting in lower PPVs (47.7–54.4% vs. 58.4%).
Conclusion
Diverging recommendations and variable performance of different guidelines may be im-
peding national diabetes prevention and treatment efforts. Efforts to align screening recom-
mendations may result in earlier identification of adults at high risk for prediabetes
and diabetes.
Introduction
Diabetes is a leading cause of death, disability, and health care costs in the United States (US)
[1,2]. Twenty-nine million Americans have diabetes, though a quarter of them remain unaware
of their condition [1]. Additionally, an estimated 86 million Americans have prediabetes [1], a
precursor phase in which blood glucose is not yet in the diagnostic range for diabetes, but in-
creases one’s risk of developing type 2 diabetes five- to twelve-fold [3]. Only eleven percent of
people with prediabetes are aware of having this condition [4]. Awareness gaps are likely to im-
pede implementation of evidence-based interventions to prevent diabetes [5,6] and its compli-
cations [7] among adults with prediabetes and diabetes, respectively.
While the prevalence of diabetes and prediabetes continues to grow in the US [8,9], screen-
ing for both of these conditions is hotly debated [10,11]. Diabetes meets many of Wilson and
Junger’s criteria for screening [12]: it is a major public health issue; there is an identifiable pre-
cursor phase (prediabetes); there are well-accepted glucose testing approaches to identify risk;
evidence-based lifestyle and pharmaceutical interventions exist to prevent and control diabetes;
and delayed diagnosis leads to progressive organ damage [7,13]. To date, most expert groups
have recommended offering glucose testing to individuals deemed to be at high-risk for diabe-
tes [10,14,15]. As such, various expert groups (e.g., the US Preventive Services Task Force
[USPSTF] [16], American Diabetes Association [ADA] [17], UK National Institute of Health
and Care Excellence [18], among others) have proposed guidelines that recommend whom to
test and when. However, little is known about the extent to which these targeted screening rec-
ommendations are applied in the U.S. population (i.e., whether those eligible based on guide-
lines actually receive glucose testing). Secondly, little is known about the performance of these
guidelines in identifying diabetes and prediabetes in the United States.
The objectives of this study were: 1) to estimate the proportion of the non-diabetic popula-
tion that is eligible for diabetes and pre-diabetes screening as recommended by the two most
cited US guidelines (USPSTF-2008 and ADA); 2) to estimate the proportion of those eligible
for screening who reported receiving glucose testing in the past three years; 3) to examine fac-
tors associated with self-reported glucose testing by eligibility status; and 4) to examine the ex-
tent to which, by applying the two screening guidelines, dysglycemia is actually identified.
Although they have explicitly different goals, we used these two guidelines since USPSTF crite-
ria are commonly used to set health and preventive service coverage levels nationally, and
ADA annually provides authoritative diabetes care and prevention recommendations. At the
time of submission, USPSTF proposed changes to the screening recommendation, including
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screening for abnormal blood glucose and type 2 diabetes mellitus in adults with known risk
factors for impaired fasting glucose, impaired glucose tolerance, or diabetes [19]. In anticipa-
tion of this change to the USPSTF guideline, we also examined self-reported glucose testing
patterns by selected major risk factors. These findings have important implications for improv-
ing screening practice yields as well as reducing inefficiencies of superfluous testing.
Methods
Data source
Data were from the 2007–2012 National Health and Nutrition Examination Surveys
(NHANES). NHANES uses a complex, multistage probability sampling design, allowing na-
tionally-representative descriptive statistics of the health status of the non-institutionalized US
civilian population [20, 21]. Interview data are collected at households while standardized mea-
surements and biological samples are collected at mobile examination centers. NHANES data
are released in 2-year increments. Overall response rates for completing the examination were
75.4%, 77.3%, and 69.5% for the 2007–2008, 2009–2010, and 2011–2012 surveys, respectively.
Study participants
NHANES adult participants (aged20 years) who had fasted 8-<24 hours were included in
the study. We excluded those reporting a previous diagnosis of diabetes (n = 920), pregnant
women (n = 70), and participants with missing information (n = 494) regarding diabetes risk
factors, receipt of glucose testing, or glycemic measures. The final analytic sample included
5,813 participants.
Ethics statement
NHANES received approval for human subjects research from the Research Ethics Review
Board of the Centers for Disease Control and Prevention’s National Center for Health Statis-
tics. Adult participants provided written informed consent.
Measurements and case definitions
NHANES survey instruments and protocols have been described extensively [20,21]. Each
screening guideline defined people at risk for diabetes, and therefore eligible to receive glucose
screening tests, based on a different set of risk factors. We identified variables in the NHANES
survey to match these sets of risk factors for dysglycemia (Table 1). For ADA guidelines [17],
risk factors included age45 years; body mass index (BMI [calculated as weight in kilograms
divided by height in meters squared]25 kg/m2); physical inactivity (e.g., no work-, transport-
, or recreation-related physical activity in a typical week); family history of diabetes in a first-
degree relative; high-risk ethnicity (e.g., non-Hispanic black, Hispanic, and those who did not
identify as non-Hispanic white); history of delivering a macrosomic baby or having gestational
diabetes; hypertension (average of three blood pressure readings140/90 mmHg, regardless of
antihypertensive medication use); dyslipidemia (HDL-cholesterol<35 mg/dL, triglycerides
>250 mg/dL, regardless of lipid-lowering medication use); self-reported diagnosis of prediabe-
tes (i.e., impaired fasting glucose, impaired glucose tolerance, or borderline diabetes); and self-
reported history of vascular disease (e.g., myocardial infarction, coronary heart disease, or
stroke). NHANES did not collect data on history of polycystic ovary syndrome, which is also a
risk factor for dysglycemia according to ADA guidelines. For USPSTF-2008 guidelines [16], we
defined high-risk as having an average of three blood pressure readings>135/80 mmHg, re-
gardless of antihypertensive medication use.
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We also identified adults with any major risk factor of: age45 years, body mass index25
kg/m2, family history of diabetes, high-risk ethnicity, history of gestational diabetes, blood
pressure140/90 mmHg, or self-reported prediabetes. With the exception of self-reported
prediabetes, we selected these risk factors because of their inclusion in the proposed new
USPSTF guidelines [19]. We included self-reported prediabetes because little is known about
patterns of glucose testing and dysglycemia in this growing, high-risk population.
Eligibility for screening at the time of the survey was defined as meeting the criteria for a
given guideline. For example, eligibility based on ADA criteria included participants aged45
years or any overweight (BMI25 kg/m2) participant aged<45 years with at least one addi-
tional risk factor [17]. If an individual did not meet any criterion, then the individual was con-
sidered ineligible for glucose testing based on that specific guideline. We defined self-reported
receipt of glucose testing as an affirmative answer to the question, “Have you had a blood test
for high blood sugar or diabetes within the past three years?”
We defined dysglycemia as prediabetes or undiagnosed diabetes according to blood glucose
levels measured in NHANES. Prediabetes was defined as fasting plasma glucose (FPG) 100 to
125 mg/dL or hemoglobin A1c (A1C) 5.7 to<6.5% (39 to<48 mmol/mol). Undiagnosed dia-
betes was defined as FPG126 mg/dL or A1C6.5% (48 mmol/mol). Any dysglycemia was
Table 1. Criteria for three screening guidelines and definitions from the National Health and Nutrition
Examination Survey, 2007–2012.
ADAa,b USPSTF-2008 c
• BMI 25 kg/m2 [weight in kilograms divided by
height in meters squared] plus 1 or more risk factors:
• Average blood pressure from up to three readings
>135/80 mm Hg (regardless of antihypertensive
medication use)
• Physical inactivity [no work-, transport-, or
recreation-related physical activity in a typical week]
• Family history of diabetes in a first-degree relative
• High-risk race/ethnicity [non-Hispanic black,—
Hispanic, and others who did not identify as non-
Hispanic white]
• History of gestational diabetes or delivering a
macrosomic baby
• Hypertension [average blood pressure 140/90
mm Hg]
• Dyslipidemia [HDL-cholesterol <35 mg/dl or
triglycerides >250 mg/dl]
• History of prediabetes [self-reported prediabetes,
impaired fasting glucose, impaired glucose
tolerance, or borderline diabetes]
• History of vascular disease [self-reported
myocardial infarction, coronary heart disease, or
stroke]
Or
• Age 45 years
USPSTF, United States Preventive Services Task Force; ADA, American Diabetes Association; NICE,
National Institute for Health and Clinical Excellence; BMI, body mass index.
a Standards of medical care in diabetes—2006. Diabetes Care 2006; 29 Suppl 1: S4–42.
b NHANES did not collect data on polycystic ovary syndrome which is considered a risk factor by
ADA guidelines
c Screening for type 2 diabetes mellitus in adults: U.S. Preventive Services Task Force recommendation
statement. Annals of Internal Medicine 2008; 148(11): 846–54.
doi:10.1371/journal.pone.0125249.t001
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defined as: A1C5.7% or FPG100 mg/dL [17]. A subgroup of participants also completed
an oral glucose tolerance test (OGTT; n = 5,337); therefore, we were able to include 2-hour
plasma glucose values (2hrPG) in a second, more conservative, definition of “confirmed” dys-
glycemia [17,22], defined as meeting all of three criteria: FPG100 mg/dL, 2hrPG140 mg/
dL [23], and A1C5.7% (39 mmol/mol).
Statistical analysis
Our goal was to provide information to clinicians about not only screening practices but the
characteristics of adults who reported testing (whether they were actually tested or not) to help
them better identify high risk adults. We used SAS, version 9.3 (SAS Institute, Cary, North Ca-
rolina) and SAS-callable SUDAAN, version 11 (Research Triangle Park, NC) for statistical
analyses, accounting for NHANES’ complex survey design. We estimated the proportion of
adults self-reporting receipt of glucose testing in the past three years by eligibility based on
each guideline using cross-tabulations (eligible and tested, eligible and not tested, ineligible and
tested, ineligible and not tested). We then compared factors associated with glucose testing
among mutually exclusive groups according to eligibility status based on current US guidelines
(i.e., USPSTF-2008 and ADA). Using logistic regression modeling, we also calculated crude
prevalence estimates for self-reported glucose testing by major risk factors and prevalence ra-
tios, adjusted for age, sex, race/ethnicity, education, income, insurance status, and usual place
of care. Finally, we assessed the performance (sensitivity, specificity, positive predictive value
[PPV], and negative predictive value [NPV]) of the screening guidelines to identify dysglyce-
mia and undiagnosed diabetes using blood glucose levels measured in the NHANES as the
gold standard.
Results
In 2007–2012, 23.7% and 73.0% of US adults without diagnosed diabetes met USPSTF-2008
and ADA eligibility for glucose testing, respectively; while 91.5% of adults had at least one
major diabetes risk factor (Fig 1). Extrapolating to the 2013 Census population aged20 years
without diagnosed diabetes (approximately 213,887,500), these percentages represent roughly
50.8 million, 156.2 million, and 195.7 million adults at risk for diabetes, respectively. Of those
USPSTF- or ADA-eligible, 50.7% [48.4–52.9] reported receiving glucose testing within the past
three years. During the 6-year period, estimates of self-reported glucose testing significantly in-
creased among ADA-eligible (47.0% [45.0–48.9] in 2007–2008 to 55.4% [51.1–59.6] in 2011–
2012; P = 0.005) but not USPSTF-eligible adults (48.5% [43.7–53.3] to 54.8% [49.3–60.2];
P = 0.24) (data not shown). Greater proportions of eligible adults aged45 years compared to
their younger eligible counterparts aged<45 years reported receiving glucose testing within
the past three years: 55.1% vs 42.4% (USPSTF-2008) and 55.6% vs 41.3% (ADA); both P-
values<0.01 (data not shown). Based on the USPSTF-2008 guidelines, 33.6% of US adults were
ineligible but still reported receiving testing. Similarly, 8.3% of adults reported being tested and
were classified as ineligible by ADA criteria; while only 1.9% of the population had no major
risk factors but reported being tested (Fig 1).
Examining the commonly-used US practice guidelines, about 21% of non-diabetic US adults
were eligible for glucose testing based on both ADA and USPSTF-2008 guidelines, while almost
52% were eligible based on ADA criteria alone and 25% were ineligible on both ADA and
USPSTF-2008 guidelines. Only about 2% were USPSTF-eligible, but not ADA-eligible. (data
not shown).
Table 2 shows sociodemographic and clinical factors associated with glucose testing accord-
ing to ADA and USPSTF-2008 screening eligibility. Non-diabetic U.S. adults who were
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classified as eligible for glucose testing based on both guidelines and were tested tended to be
older, have higher mean BMI, or have larger waist circumferences, compared with those eligi-
ble but not tested (P-values<0.001). For adults only eligible based on ADA and not USPSTF-
2008 guidelines, those tested tended to be older or more likely to be female or more educated
than those not tested (P-values<0.01). Of those that were ADA- and USPSTF-eligible or just
ADA-eligible, those not receiving glucose testing were more likely to be younger, poorer, unin-
sured, or have no usual place of care compared to those receiving testing (P-values<0.05).
Even among those that were ineligible by both guidelines, a higher proportion of those not test-
ed were uninsured (P = 0.001) or had no usual place of care compared to those tested
(P = 0.01). Compared to non-diabetic U.S. adults that were ADA-eligible for glucose testing,
higher proportions of combined USPSTF- and ADA-eligible adults had dysglycemia (range:
55.6–67.7% vs. 44.6–57.8% [ADA only]). Of the group that both guidelines classified as ineligi-
ble, 16.9–18.6% had prediabetes and0.2% had undiagnosed diabetes. Additionally, among
those eligible by either ADA or USPSTF-2008 criteria, receipt of glucose testing was indepen-
dently associated with age, education, insurance coverage, usual place of care, and BMI, even
after controlling for sociodemographic and clinical characteristics (data not shown).
Table 3 shows crude prevalence estimates and adjusted prevalence ratios for self-reported
glucose testing and dysglycemia according to major risk factor subgroups. Overall, compared
to non-diabetic adults without any major risk factors, those with at least one were 63% more
likely to report receiving a glucose test in the past 3 years and 93% more likely to have dysglyce-
mia (P-values<0.001). Glucose testing estimates were highest among non-diabetic adults with
Fig 1. Percentage of US adults reporting receipt of glucose testing by eligibility status according to
diabetes screening guidelines. Abbreviations: USPSTF, United States Preventive Services Task Force;
ADA, American Diabetes Association. Data were from 5,813 adults without diagnosed diabetes in the 2007–
2012 National Health and Nutrition Examination Survey. Receipt of glucose testing was defined as an
affirmative answer to the question, “Have you had a blood test for high blood sugar or diabetes within the past
three years?” Any risk factor is defined as: age45 years, body mass index 25 kg/m2, family history of
diabetes, high-risk ethnicity, history of gestational diabetes or prediabetes, or blood pressure140/90
mmHg.
doi:10.1371/journal.pone.0125249.g001
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Table 2. Characteristics of adults without diagnosed diabetes according to US guideline eligibility groupsa who did and did not report receipt of
glucose testingb in past 3 years.
Total Eligible based on both
ADA and USPSTF
Eligible based on ADA,
but not USPSTF


















Unweighted n 3040 2773 682 783 1515 1613 770 342
Population size (millions) 99.6 83.8 18.3 20.8 47.0 47.9 31.3 13.7
Age (years), % (SE)
20–44 years 58.6 (1.4) 38.3 (1.6)** 26.4 (1.9 20.6 (2.1)** 41.0 (2.1) 26.5 (1.6)** 100.0 100.0
45–64 years 31.5 (1.3) 40.9 (1.5) 48.7 (2.1) 48.3 (2.2) 47.8 (2.1) 50.6 (1.7) n/a n/a
65 years 9.9 (0.5) 20.8 (0.8) 25.0 (1.9) 31.1 (1.9) 11.3 (0.9) 22.9 (1.0) n/a n/a
Age (years), mean (SE) 42.1 (0.4) 50.2 (0.5)** 53.9 (0.6) 57.3 (0.6)** 46.1 (0.6) 52.7 (0.5)** 30.0 (0.3) 32.1 (0.5)
**
Male, % (SE) 51.8 (1.0) 44.6 (1.1)** 54.7 (2.3) 49.9 (1.9) 50.9 (1.4) 43.0 (1.7)** 49.4 (2.1) 39.7 (3.3)*
Race/ethnicity, % (SE) c
NH white 68.0 (2.0) 70.1 (2.2)** 63.8 (3.3) 68.7 (3.0) 63.8 (2.5) 69.3 (2.4)** 76.2 (1.9) 75.2 (2.9)
NH black 9.9 (1.0) 11.7 (1.1) 15.1 (1.7) 15.5 (2.0) 10.1 (1.1) 11.8 (1.2) 6.7 (0.9) 5.0 (0.9)
Hispanic 14.8 (1.5) 12.3 (1.4) 13.3 (1.9) 10.9 (1.5) 19.6 (2.0) 13.8 (1.6) 9.3 (1.3) 9.9 (1.4)
Education <HS, % (SE) 18.1 (1.1) 16.4 (1.1) 21.5 (2.3) 18.8 (1.8) 21.0 (1.5) 16.5 (1.3)** 11.7 (1.6) 13.4 (2.3)
At or below poverty, % (SE) 16.7 (1.2) 12.3 (0.9)** 18.6 (2.1) 12.1 (1.5)** 16.0 (1.1) 11.9 (1.1)** 16.4 (1.6) 14.4 (2.1)
Uninsured, % (SE) 27.4 (1.1) 12.9 (0.8)** 23.8 (1.8) 13.4 (1.5)** 27.2 (1.5) 11.4 (1.1)** 29.3 (2.3) 17.9 (2.4)
**
No usual place of care, % (SE) 21.3 (1.0) 7.3 (0.6)** 19.1 (1.7) 6.1 (1.0)** 21.1 (1.3) 5.6 (0.7)** 22.4 (2.0) 14.4 (2.0)*
Physical inactivity, % (SE) 18.8 (1.1) 21.0 (1.0) 24.9 (2.0) 26.3 (1.7) 23.9 (1.6) 23.3 (1.7) 8.5 (1.1) 6.7 (1.0)
BMI (kg/m2), mean (SE) 27.3 (0.1) 29.3 (0.2)** 29.2 (0.3) 31.3 (0.4)** 28.8 (0.2) 30.0 (0.2)** 23.9 (0.2) 24.4 (0.3)
Waist circumference (cm), mean
(SE)
94.5 (0.4) 100.3 (0.4)
**
101.0 (0.6) 106.0 (0.7)
**
98.6 (0.5) 102.0 (0.5)
**
84.8 (0.5) 86.7 (1.0)*
SBP (mmHg), mean (SE) 118.4 (0.4) 120.7 (0.4)
**
138.3 (0.8) 140.3 (0.8) 115.2 (0.4) 115.3 (0.3) 110.8 (0.5) 109.4 (0.6)
DBP (mmHg), mean (SE) 69.8 (0.4) 70.2 (0.4) 80.6 (0.6) 79.3 (0.7) 67.5 (0.3) 67.0 (0.3) 65.5 (0.5) 66.0 (0.6)
FPG (mg/dL), mean (SE) 95.9 (0.3) 99.5 (0.4)** 101.4 (0.8) 103.6 (1.0) 97.4 (0.5) 100.3 (0.5)
**
90.6 (0.4) 91.3 (0.6)
A1c (%), mean (SE) 5.4 (0.01) 5.5 (0.01)** 5.6 (0.03) 5.7 (0.03)* 5.5 (0.02) 5.6 (0.01)** 5.2 (0.01) 5.2 (0.02)
PreDM, % (SE) 35.2 (1.1) 48.0 (1.3)** 49.6 (2.7) 58.8 (3.1)* 42.4 (1.8) 52.1 (1.4)** 16.9 (1.6) 18.6 (2.5)
DM, % (SE) 2.2 (0.3) 5.4 (0.5)** 6.0 (0.9) 8.5 (1.3) 2.2 (0.4) 5.7 (0.7)** 0.1 (0.1) d 0.2 (0.2) d
N = 5813, representing 183 million adults without diagnosed diabetes
Abbreviations: USPSTF, United States Preventive Services Task Force; ADA, American Diabetes Association; HS, high school; BMI, body mass index;
FPG, fasting plasma glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; preDM, prediabetes defined by FPG 100–125 mg/dL or A1C
5.7–6.4%; DM, diabetes defined by FPG 126 mg/dL or A1C 6.5%.
a Insufficient sample size for participants eligible for screening based on USPSTF but not ADA criteria (n = 108, representing 4.4 million adults without
diagnosed diabetes).
b Defined as an affirmative answer to the question, “Have you had a blood test for high blood sugar or diabetes within the past three years?”
c Participants of other race/ethnicity included in analysis, but results not shown
d Unstable estimate due to insufficient sample size or relative standard error greater than 30%.
* P-value <0.05;
**P-value <0.01 for comparing tested and not tested, calculated from Wald F test or t test.
doi:10.1371/journal.pone.0125249.t002
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the following risk factors: previous diagnosis of prediabetes (80.3%), gestational diabetes
(57.1%), age45 years (55.6%), followed by high blood pressure (54.4%). Prevalence of glucose
testing ranged 44.0–50.2% for non-diabetic overweight adults, those with a family history of di-
abetes, or those of high-risk ethnicity. Each risk factor was significantly associated with dysgly-
cemia, independent of sociodemographic characteristics. Those with individual risk factors
had 12 to 117% greater prevalence of dysglycemia compared to those without risk factors;
while, dysglycemia prevalence exceeded 60% only for those aged45 years, those with high
blood pressure, and those with a history of prediabetes.
Table 3. Prevalence of self-reported receipt of glucose testing in past 3 years and dysglycemia according to selectedmajor risk factors among US
adults without diagnosed diabetes.
Represented
Populationa









n, millions % (SE) PR (95% CI) % (SE) PR (95% CI)
Total 183.4 45.7 (1.0) 44.7 (1.0)
Age
20–44 y (reference) 90.5 35.5 (1.2) 1.00 28.5 (1.3) 1.00
45 y 92.9 55.6 (1.3) 1.44 (1.31, 1.57) 60.5 (1.2) 2.17 (1.96, 2.41)
Overweight or obese
<25 kg/m2 (reference) 61.2 36.8 (1.6) 1.00 31.7 (1.7) 1.00
25 kg/m2 121.0 50.2 (1.0) 1.32 (1.21, 1.44) 51.3 (1.1) 1.45 (1.30, 1.63)
Family history of diabetes
No (reference) 122.4 43.6 (1.3) 1.00 41.7 (0.9) 1.00
Yes 61.0 49.9 (1.5) 1.12 (1.03, 1.21) 50.7 (1.8) 1.18 (1.09, 1.28)
High-risk ethnicity
No (reference) 126.5 46.5 (1.2) 1.00 44.2 (1.3) 1.00
Yes 56.9 44.0 (1.3) 1.12 (1.05, 1.20) 45.8 (1.3) 1.12 (1.03, 1.21)
History of gestational
diabetes
No (reference) 169.1 44.7 (1.0) 1.00 44.2 (1.0) 1.00
Yes 14.3 57.1 (2.9) 1.15 (1.02, 1.29) 50.3 (3.2) 1.19 (1.05, 1.34)
Hypertension
No (reference) 161.6 44.5 (1.1) 1.00 41.8 (1.1) 1.00
Yes 21.8 54.4 (2.0) 1.11 (1.01, 1.22) 66.4 (2.2) 1.27 (1.15, 1.40)
History of prediabetes
No (reference) 174.7 44.0 (1.0) 1.00 43.3 (1.0) 1.00
Yes 8.7 80.3 (2.7) 1.69 (1.54, 1.84) 72.6 (3.3) 1.55 (1.37, 1.76)
Any risk factore
No (reference) 15.5 22.2 (2.8) 1.00 12.1 (2.4) 1.00
Yes 167.9 47.9 (1.0) 1.63 (1.31, 2.03) 47.7 (1.0) 1.93 (1.33, 2.82)
Abbreviations: SE, standard error; PR, prevalence ratio.
a Population sizes may not sum to 183 million due to rounding
b Defined as an affirmative answer to the question, “Have you had a blood test for high blood sugar or diabetes within the past three years?”
c Defined as fasting plasma glucose 100 mg/dL or A1c 5.7%
d Estimated from logistic regression models, adjusted for age, sex, race/ethnicity, education, income, insurance status, and usual place of care
e Defined as any of: age 45 years, body mass index 25 kg/m2, family history of diabetes, high-risk ethnicity, history of gestational diabetes, blood
pressure 140/90 mmHg, or self-reported prediabetes.
doi:10.1371/journal.pone.0125249.t003
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Regarding performance of the guidelines, Table 4 provides estimates of sensitivity, specifici-
ty, PPV, and NPV (and respective 95% CI’s) for each of the three screening guidelines using
NHANES laboratory tests as the standard for identifying any dysglycemia,”confirmed” dysgly-
cemia, and undiagnosed diabetes. Compared with USPSTF-2008 guidelines, ADA criteria were
more sensitive in identifying those with any dysglycemia (Percentage of true positives over all
positives for USPSTF-2008: 31.0% [29.0, 33.1] vs. ADA: 88.8% [87.0, 90.4]) but less specific
(Percentage of true negatives over all negatives: 82.1% [79.7, 84.3] vs. 39.7% [36.8, 42.7]). Re-
stricting to an increasingly more conservative definition of dysglycemia, both guidelines
yielded better sensitivity and declining specificity. Using any major risk factor to identify dys-
glycemia yielded the highest sensitivity and lowest specificity compared to ADA and USPSTF-
2008 guidelines.
Among adults that the USPSTF-2008 guidelines recommended for glucose testing, 58.4%
(54.5, 62.1) actually had any dysglycemia, while this PPV was 54.4% (52.1, 56.4) and 47.7%
(45.7, 49.8) for the ADA criteria and any major risk factor, respectively. Among those with
“confirmed” dysglycemia or undiagnosed diabetes, the PPV of both guidelines diminished con-
siderably, ranging from 4.9% to 13.9%. However, those that the guidelines identified as
Table 4. Performancea of screening criteria in identifying dysglycemia among US adults without diagnosed diabetes.
Dysglycemia definition Guideline Sensitivity b Specificity c PPV d NPV e




















All 3 of: FPG 100 mg/dL, A1c 5.7% f, and 2hrPG
140 mg/dL h
















8.8 (7.7, 10.1) 8.7 (7.7, 9.8) 99.8 (98.7,
100.0)
Undiagnosed DM (FPG 126 mg/dL or A1c 6.5% f) USPSTF-2008 42.9 (35.0, 51.1) 77.0 (75.3,
78.6)
6.6 (5.3, 8.2) 97.3 (96.7,
97.7)
ADA 98.7 (97.3, 99.4) 27.9 (25.9,
30.1)




99.4 (97.3, 99.9) 8.8 (7.6, 10.1) 4.0 (3.5, 4.6) 99.7 (98.8,
99.9)
Abbreviations: PPV, positive predictive value; NPV, negative predictive value; USPSTF, United States Preventive Services Task Force; ADA, American
Diabetes Association; DM, diabetes mellitus; FPG, fasting plasma glucose; 2hrPG, 2-hr plasma glucose from an oral glucose tolerance test.
a Data are presented as weighted percentages and 95% confidence intervals based on data from 5,813 adults without diagnosed diabetes, representing
183 million
b Probability of being eligible for screening among those with dysglycemia (true positives)
c Probability of being ineligible for screening among those without dysglycemia (true negatives)
d Probability of having dysglycemia among those eligible for screening
e Probability of not having dysglycemia among those ineligible for screening
f A1c values 5.7% and 6.5% correspond to A1c values 39 mmol/mol and 48 mmol/mol.
g Defined as any of: age 45 years, body mass index 25 kg/m2, family history of diabetes, high-risk ethnicity, history of gestational diabetes, blood
pressure 140/90 mmHg, or self-reported prediabetes
h Subpopulation of adults with available 2-hour PG values; N = 5,337.
doi:10.1371/journal.pone.0125249.t004
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ineligible for glucose testing, the proportion without “confirmed” dysglycemia or undiagnosed
diabetes (or the NPV) neared 100%.
Discussion
Amidst the large and growing national diabetes burden and intense debates regarding how to
improve detection, our study is the first national-level assessment—of which we are aware—
that both compares screening guideline performance and examines receipt of glucose testing
by eligibility and major factor status. Our findings show wide variation across US expert guide-
lines in terms of proportions of US adults eligible for glucose testing, as well as wide variation
in the yield of testing when guidelines are applied (i.e. PPV). Even so, and importantly, gaps
exist in testing practices as only 50–60% of US adults who met any of the glucose testing criteria
reported receiving testing (i.e. appropriate testing).
Among those eligible by either US guideline or just ADA guidelines, individuals not receiv-
ing glucose testing were more likely to have low education, low household income, and to lack
health insurance or a usual health care provider than individuals who received testing. These
factors may also be interconnected, as health insurance is linked to the likelihood of having a
usual care provider. As a comparison, a study examining electronic medical records of 46,991
persons attending a large academic physician practice during 2005–2007 showed that 72.0%
met either USPSTF or ADA criteria for screening, and 85.3% of them received glucose testing
[24]. This same analysis also showed a sizeable difference in glucose testing uptake between un-
insured (54.9%) and insured (85.4%). It will be important to continue to evaluate glucose test-
ing practices as access to preventive services changes, especially for lower socioeconomic
groups.
It is expected that future USPSTF-approved preventive services will be provided without
cost-sharing [25] which elevates the importance of this particular guideline’s predictive validity
for identifying dysglycemia. As demonstrated in our data and previous reports [24,26],
USPSTF-2008 criteria are the least sensitive, resulting in glucose testing in only half of all dys-
glycemia cases. This may be in part because USPSTF criteria were developed to identify undi-
agnosed diabetes. In 2014, USPSTF proposed screening for abnormal blood glucose and type 2
diabetes mellitus in adults who are at increased risk for diabetes although the final, specific risk
factor criteria were yet to be published at the time of this submission [19]. This change better
aligns with the screening criteria of the ADA and organizations that endorse using risk assess-
ment tools to identify adults at high risk. Applying the 2008 USPSTF guideline to the 2013
Census adult population without diagnosed diabetes would identify at least 50 million adults;
while proposed changes could potentially identify 91.5% of the non-diabetic population, or 195
million adults, eligible for glucose testing.
Earlier detection is important. In the Diabetes Prevention Program Outcomes Study, pro-
viding intensive lifestyle modification to the intervention group three years earlier than the
control group continues to have incremental benefits in terms of cumulative incidence of dia-
betes, need for medications, as well as hypertension and lipid control [5]. In addition, those
achieving improved beta-cell function and even transient regression to normal glucose levels
experienced lower conversion to diabetes [27]. Lastly, 10–20% of persons newly diagnosed
with diabetes have retinopathy [28] and national surveillance shows that 41.7% of those with
undiagnosed diabetes and 17.7% of people with prediabetes have chronic kidney disease [29].
Almost half of all undiagnosed cases of diabetes have hypertension, lipid abnormalities, or car-
diovascular and chronic kidney diseases [26]. Delayed diagnosis hinders the possibility of earli-
er intervention to slow the disease processes of dysglycemia and its co-morbidities.
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On the other hand, as a result of the ADA criteria’s lower thresholds for recommending
testing, approximately three-quarters of the United States’ entire non-diabetic adult population
(~200 million people) would become eligible for glucose testing. Though our data show that
this would identify over 90% of dysglycemia of any form, there would be higher costs and inef-
ficiencies (i.e. low yield) associated with this population-wide screening approach. There is an
ongoing debate regarding cost-effectiveness of universal screening versus offering glucose test-
ing to only high-risk individuals. With universal testing, likelihood of low yield (perhaps due to
low prevalence in the population) and subsequent over-testing and excess costs are concerns,
especially for those younger than 35 years old [15]. With targeted testing, an extra step of risk
assessment is needed, and since current risk assessment guidelines recommend varied thresh-
olds within (e.g., USPSTF-2008 and ADA) and across populations (e.g., there are European, In-
dian, and other race/ethnicity group risk scores) at which a glucose test should be offered, the
balance between missed cases, over-testing, and costs becomes blurred and unclear. Others
have raised concerns about collateral harms of such widespread testing, including physical dis-
comfort (e.g., pain) and potentially psychosocial harms like increased anxiety [30] or discrimi-
nation, although recent studies suggest that psychological impacts are minimal and diminish
with time [10,31].
Since resources are required to care for the added burden of cases that are newly detected
through screening, some guidelines also consider cost-effectiveness data. The cost-effectiveness
of screening for dysglycemia depends both on the yield in the population as well as the cost-ef-
fectiveness of interventions to address prediabetes or diabetes [32,33]. Structured lifestyle mod-
ification and metformin are highly cost-effective interventions for people with prediabetes
[34]. Additionally, long-term data regarding more intensive treatment in 5,102 persons with
newly-diagnosed diabetes in the United Kingdom Prospective Diabetes Study showed reduced
micro- and macro-vascular complications and deaths [7]. On the basis of these data, modeling
studies suggest screening for both prediabetes and diabetes together (dysglycemia) followed by
lifestyle or pharmacotherapies is more cost-effective than screening for just diabetes [10,14].
We therefore used dysglycemia as the outcome to evaluate screening guideline performance in
this study. Even so, our data show that the more inclusive ADA recommendation has low spec-
ificity and PPV, which would likely result in misused resources if greater proportions of those
eligible were to actually receive testing.
Our study is subject to a few limitations. We considered unidentified individuals with diabe-
tes and prediabetes based on elevated FPG or A1C values only. Since we chose not to include
OGTT data in all analyses, the prevalence of dysglycemia might be underestimated in our
study population. Adults with previously diagnosed prediabetes were included in the analysis,
as this is one of ADA’s criteria. Excluding these individuals had little influence on our findings.
Furthermore, our estimates are based on cross-sectional measures which limit inferences of
true, longitudinal predictive validity. Also, prevalence estimates for self-reported glucose test-
ing may be subject to some uncertainty. Receipt of glucose testing may be underreported due
to recall bias and glucose tests conducted, either singly or as part of a blood test panel, without
the patient’s knowledge. Prevalence may also be overestimated and could vary according to pa-
tient characteristics. For example, individuals with a family history of diabetes may be more
aware of their risk and therefore more likely to report testing whether it occurred or not. Simi-
larly, women with a history of GDM and older adults who have more engagement with the
health care system may over-report their glucose testing history. However, despite the potential
errors in reporting, on a national scale, self-report remains the only viable method of measur-
ing receipt of glucose testing as claims data currently do not cover a representative sample of
the whole country. Second, self-reported glucose testing remains an important indicator to
monitor over time in light of the growing diabetes epidemic and evolving recommendations
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for screening adults at high risk for diabetes. In addition, we have no information on the type
of glucose testing received (e.g., random versus fasting versus OGTT), though there is variation
in performance across tests. There may also be misclassification of glycemic status and charac-
teristics due to the gap between the time when participants received glucose testing and when
they were surveyed. Lastly, revisions to the USPSTF guideline were being considered but had
not been finalized at the time of publication. Preliminary communication [19] suggests that the
new USPSTF guidelines will encourage testing for persons with any major diabetes risk factor
(i.e., age, family history, BMI, etc.) and therein be more aligned with ADA guidelines than the
prior USPSTF guidelines. Although these recommendations have not been finalized, one of
our goals was to compare the performance of both USPSTF guidelines (2008 recommendation
vs the newer “any major risk factor” recommendation) to examine the potential impact of
changes to this guideline on the population at risk as well as patterns of glucose testing by risk
factor status.
Despite these limitations, our data are nationally-representative, recent, and the substantial
sample size provides stable robust estimates. We evaluated two US guidelines and had variables
for all of the most common diabetes risk factors. Additionally, screening guideline performance
was comprehensively examined using sensitivity, specificity, PPV, and NPV measures.
Conclusions
Prediabetes and diabetes prevalence continue to grow in the United States. Primary prevention
programs are being initiated across states, delivering evidence-based lifestyle modification pro-
grams [35]. Health reforms are underway which may improve access and transform healthcare
from a fee-for-service to fee-for-quality paradigm, which, in turn, may impact current gaps in
diabetes care [36]. However, all of these efforts are predicated on accurately identifying people
who will benefit. As such, detection of dysglycemia is an inseparable component of diabetes
prevention and care. Which screening guideline to follow and the optimal sensitivity, specifici-
ty, or both required depends on one’s goals and the availability and accessibility of resources.
Our data show important gaps and substantial variation in guideline-recommended eligibility
for screening and performance of these tools. This divergence is important and may promote
indecisiveness and confusion among care providers. As such, to narrow the gaps and take ad-
vantage of evolving policies and practices, future steps might include multi-stage screening em-
phasizing risk scoring approaches and decision analysis. Until then, better utilization of
glucose testing guidelines is needed.
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